Tacrolimus decreases tubular phosphate wasting in renal allograft recipients.
The aim of the study was to elucidate whether cyclosporine- and tacrolimus-based immunosuppression impairs tubular reabsorption of phosphate after kidney transplantation. Sixty cadaveric allograft recipients were included in the study. Forty patients receiving triple immunosupression with cyclosporine, azathioprine, and prednisone were studied for 1, 6, 12 months (groups A1 and A2, 20 patients) and for 24, 30, and 36 months (groups B1 and B2, 20 patients) after transplantation. Twenty patients who received tacrolimus with steroid withdrawal after 3 months were included in the study (group C). Recipients from groups A2 and B2 were treated additionally with vitamin D and calcium carbonate. Serum iPTH, 25-OHD, 1.25(OH)(2)D concentrations were determined, and TRP (mmol/L) and TmP/GFR (mmol/L) were calculated using Walton-Bijvoet nomogram. Higher values of total calcium serum concentration in group A were detected. Lower inorganic phosphate serum concentrations were detected in groups A and C, in contrast to group B where they remained within normal values. TmP/GFR values were significantly higher in group C in the first and third examination in comparison with patients of group A. Moreover, TRP index values were significantly higher than analogous values of groups A and B. Tacrolimus-treated patients exhibit significantly faster recovery from tubular phosphate reabsorption impairment compared to cyclosporine-treated recipients. No correlation between iPTH, 25-OHD, 1,25(OH)(2)D concentration, and tubular dysfunction parameters was observed. Amelioration of phosphate handling, in spite of hyperparathyroidism intensity, can follow early steroid avoidance.
Falkiewicz
K
K
Department of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland. klinef@am.centrum.pl
Nahaczewska
W
W
Boratynska
M
M
Owczarek
H
H
Klinger
M
M
Kaminska
D
D
Wozniak
M
M
Szepietowski
T
T
Patrzalek
D
D
D000293:Adolescent; D000328:Adult; D002102:Cadaver; D002119:Calcium Carbonate / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007684:Kidney Tubules / Q000187:drug effects / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000378:metabolism; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*; D014807:Vitamin D / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D010710:Phosphates; D014807:Vitamin D; D002119:Calcium Carbonate; D016559:Tacrolimus